Literature DB >> 27787613

Myeloid-derived suppressor cells and tumor escape from immune surveillance.

Viktor Umansky1,2, Carolin Blattner3,4, Viktor Fleming3,4, Xiaoying Hu3,4, Christoffer Gebhardt3,4, Peter Altevogt3,4, Jochen Utikal3,4.   

Abstract

Tumor progression is known to be supported by chronic inflammatory conditions developed in the tumor microenvironment. It is characterized by the long-term secretion of various inflammatory soluble factors (including cytokines, chemokines, growth factors, reactive oxygen and nitrogen species, prostaglandins, etc.) and strong leukocyte infiltration. Among leukocytes infiltrating tumors, myeloid-derived suppressor cells (MDSCs) represent one of the most important players mediating immunosuppression and supporting tumor escape. These cells can strongly inhibit antitumor immune reactions mediated by T cells and NK cells. Moreover, MDSCs are generated, recruited to the tumor site, and activated not only under the influence of soluble inflammatory mediators but also due to extracellular vesicles (EVs) secreted by tumor cells. EVs play a key role in the formation of MDSCs via the conversion of normal myeloid cells and altering the normal myelopoiesis. In addition, EVs help create a suitable microenvironment for the metastatic process.

Entities:  

Keywords:  Cancer; Chronic inflammatory factors; Extracellular microvesicles; Immunosuppression; Myeloid-derived suppressor cells; Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27787613     DOI: 10.1007/s00281-016-0597-6

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  109 in total

Review 1.  Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Authors:  Michail V Sitkovsky; Stephen Hatfield; Robert Abbott; Bryan Belikoff; Dmitriy Lukashev; Akio Ohta
Journal:  Cancer Immunol Res       Date:  2014-07       Impact factor: 11.151

Review 2.  New insights into chronic inflammation-induced immunosuppression.

Authors:  Julia Kanterman; Moshe Sade-Feldman; Michal Baniyash
Journal:  Semin Cancer Biol       Date:  2012-02-24       Impact factor: 15.707

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

4.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

Review 5.  New therapeutic options for advanced non-resectable malignant melanoma.

Authors:  Simone Stadler; Kasia Weina; Christoffer Gebhardt; Jochen Utikal
Journal:  Adv Med Sci       Date:  2014-12-25       Impact factor: 3.287

6.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Authors:  Alexander M Lesokhin; Tobias M Hohl; Shigehisa Kitano; Czrina Cortez; Daniel Hirschhorn-Cymerman; Francesca Avogadri; Gabrielle A Rizzuto; John J Lazarus; Eric G Pamer; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Res       Date:  2011-12-15       Impact factor: 12.701

Review 7.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

8.  The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness.

Authors:  A Ginestra; M D La Placa; F Saladino; D Cassarà; H Nagase; M L Vittorelli
Journal:  Anticancer Res       Date:  1998 Sep-Oct       Impact factor: 2.480

9.  Melanoma miRNA trafficking controls tumour primary niche formation.

Authors:  Shani Dror; Laureen Sander; Hila Schwartz; Danna Sheinboim; Aviv Barzilai; Yuval Dishon; Sebastien Apcher; Tamar Golan; Shoshana Greenberger; Iris Barshack; Hagar Malcov; Alona Zilberberg; Lotan Levin; Michelle Nessling; Yael Friedmann; Vivien Igras; Ohad Barzilay; Hananya Vaknine; Ronen Brenner; Assaf Zinger; Avi Schroeder; Pinchas Gonen; Mehdi Khaled; Neta Erez; Jörg D Hoheisel; Carmit Levy
Journal:  Nat Cell Biol       Date:  2016-08-22       Impact factor: 28.824

10.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Authors:  Bin Zhang; Zhijun Wang; Liangliang Wu; Meng Zhang; Wei Li; Jianhua Ding; Jun Zhu; Huafeng Wei; Ke Zhao
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more
  24 in total

Review 1.  Cancer and autoimmunity.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2017-03-27       Impact factor: 9.623

2.  Role of liver ICAM-1 in metastasis.

Authors:  Aitor Benedicto; Irene Romayor; Beatriz Arteta
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

Review 3.  Nanozyme-Based Enhanced Cancer Immunotherapy.

Authors:  Ngoc Man Phan; Thanh Loc Nguyen; Jaeyun Kim
Journal:  Tissue Eng Regen Med       Date:  2022-01-31       Impact factor: 4.169

Review 4.  Tumor microenvironment antigens.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2022-09-29       Impact factor: 11.759

5.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

6.  Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Authors:  Mia Aaboe Jørgensen; Morten Orebo Holmström; Evelina Martinenaite; Caroline Hasselbalch Riley; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 7.  Roles of long noncoding RNAs on tumor immune escape by regulating immune cells differentiation and function.

Authors:  Lisha Chang; Juan Li; Jie Ding; Yifan Lian; Chaonan Huangfu; Keming Wang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 8.  Cancer immunotherapy: how low-level ionizing radiation can play a key role.

Authors:  Marek K Janiak; Marta Wincenciak; Aneta Cheda; Ewa M Nowosielska; Edward J Calabrese
Journal:  Cancer Immunol Immunother       Date:  2017-03-30       Impact factor: 6.968

Review 9.  Understanding Immune Thrombocytopenia: Looking Out of the Box.

Authors:  Alexandra Schifferli; Franco Cavalli; Bertrand Godeau; Howard A Liebman; Mike Recher; Paul Imbach; Thomas Kühne
Journal:  Front Med (Lausanne)       Date:  2021-06-24

Review 10.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Authors:  Viktor Fleming; Xiaoying Hu; Rebekka Weber; Vasyl Nagibin; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.